title: Is recombinant tissue plasminogen activator an option in the treatment of meningococcus-induced purpura?
authors.forename: A
authors.initials: A
authors.lastname: Veldman
authors.forename: A
authors.initials: A
authors.lastname: Ehrenberg
authors.forename: G
authors.initials: G
authors.lastname: Jäger
authors.forename: C E
authors.initials: CE
authors.lastname: Ettingshausen
authors.forename: W
authors.initials: W
authors.lastname: Schneider
authors.forename: W
authors.initials: W
authors.lastname: Kreuz
mesh_terms: D000293:Adolescent; D002985:Clinical Protocols; D003422:Critical Care / Q000379:methods; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D011695:IgA Vasculitis / Q000382:microbiology* / Q000628:therapy*; D007223:Infant; D008297:Male; D008589:Meningococcal Infections / Q000150:complications*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012772:Shock, Septic / Q000382:microbiology*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator